Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict molecular binding affinity with unmatched speed and accuracy.
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT
